Myotonic Dystrophy Type 1 (DM1)

Rare Disease·MeSH: Myotonic Dystrophy

Prevalence

5.0 / 100K

12 drugs in development·5 companies·6 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
DYNE-251	Dyne Therapeutics, Inc. (DYN)
srp-1003	Sarepta Therapeutics, Inc. (SRPT)
zeleciment basivarsen	Dyne Therapeutics, Inc. (DYN)

Phase 2(1)

Drug	Company
WAKIX (pitolisant) - Myotonic Dystrophy (DM1)	Harmony Biosciences Holdings, Inc. (HRMY)

Preclinical(5)

Drug	Company
aro-dm1	Sarepta Therapeutics, Inc. (SRPT)
DYNE-244	Dyne Therapeutics, Inc. (DYN)
DYNE-245	Dyne Therapeutics, Inc. (DYN)
DYNE-253	Dyne Therapeutics, Inc. (DYN)
DYNE-255	Dyne Therapeutics, Inc. (DYN)

Phase 1/Phase 2(3)

Drug	Company
DYNE-101	Dyne Therapeutics, Inc. (DYN)
vx-670	VERTEX PHARMACEUTICALS INC / MA (VRTX)
vx-670	Entrada Therapeutics, Inc. (TRDA)

BioSniper tracks 12 drugs in development for Myotonic Dystrophy Type 1 (DM1) across 5 companies.

There are 6 clinical trials targeting Myotonic Dystrophy Type 1 (DM1) tracked by BioSniper.

The estimated prevalence of Myotonic Dystrophy Type 1 (DM1) is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.